Micardisplus

Telmisartan/Hydrochlorothiazide, the active ingredient in Micardisplus, is an angiotensin II receptor blocker and thiazide diuretic presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients, helping to reduce the risk of cardiovascular complications associated with hypertension. The combination leverages the vasodilatory effect of telmisartan together with the diuretic action of hydrochlorothiazide to achieve a synergistic reduction in peripheral resistance and plasma volume. GNH USA supplies Micardisplus as a licensed, GDP-compliant pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micardisplus acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to treat hypertension. Hypertension: lowers systolic and diastolic blood pressure, helping patients achieve target values. Essential hypertension: provides effective blood pressure control in primary hypertension. Renovascular hypertension: adds blood pressure reduction when used with other antihypertensives.

The most frequently reported adverse reactions with Micardisplus involve the cardiovascular and metabolic systems, while rare events may be severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling) - Acute kidney injury or significant rise in serum creatinine - Marked hypotension leading to fainting - Hyperkalemia when combined with potassium‑sparing agents - Pancreatitis (very rare)

Before initiating Micardisplus, clinicians should assess patient-specific factors and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte balance: monitor potassium and sodium levels during therapy. - Caution in hepatic impairment: dose adjustments may be required. - Avoid use in severe dehydration or volume‑depleted states. - Store at ambient temperature: keep in the original pack, protect from moisture.

Micardisplus may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment - Potassium‑sparing diuretics or supplements (risk of hyperkalemia) - Lithium (increased lithium levels) - ACE inhibitors or other ARBs (combined use may cause renal dysfunction)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (may reduce antihypertensive effect) - Other antihypertensives (additive blood pressure lowering) - Digoxin (possible increase in serum levels) - Antidiabetic agents (may require dose adjustment due to blood pressure changes)